Amerigo Allegrettoeditorial@labpulse.comFinancial ResultsBio-Rad reports Q2 revenue drop, COVID-19 sales declineFor the three months ended June 30, the Hercules, CA-based firm reported a 52% drop in COVID-19 related revenues to approximately $33 million in Q2 from approximately $69 million in the year-ago period.July 28, 2022SequencingIllumina hits Guardant with lawsuit over trade secretsFiled in U.S. District Court for the District of Delaware, the lawsuit alleges that Eltoukhy and Talasaz had access to Illumina trade secrets while they were employed with Illumina up through 2013 and 2012, respectively. The lawsuit charges that the two incorporated Guardant in 2011 while still employed by Illumina and used Illumina technology as the basis for their new company.March 17, 2022Page 1 of 1Top StoriesCancerInvivoscribe, Complete Genomics partner to develop NGS tests for cancer research, detectionUnder the terms of the deal, Invivoscribe will be responsible for the development of biomarker tests, including test controls and associated bioinformatics software. The tests will run on Complete Genomics' NGS platforms.Regulatory ApprovalSeegene obtains IVDR certification for 30 diagnostic assaysPolicy and RegulationAdvocacy groups in letter urge FDA to develop regulations for lab-developed testsCollaborationNucleai, Adlai Nortye collaborate on biomarkers for clinical trialsSponsor ContentVisit our Molecular Diagnostics Community
